Opko snaps up microcap Transition for $60M to gain GLP-1/glucagon dual agonist


Opko Health ($OPK) has paid up a little--very little, in fact--to get what it sees as the most advanced clinical candidate in the new class of GLP-1/glucagon receptor dual agonists. It did a $60 million, all-stock deal to acquire microcap Transition Therapeutics ($TTHI).

Transition never recovered after it lost most of its value last June when a Phase II/III study of its lead candidate ELND005 did not meet the primary endpoint in a study to treat agitation and aggression in Alzheimer’s disease patients.

The deal price was $1.55 per share, a valuation of more than twice its closing share price on the day before the offer of $0.70. The all-stock deal values Transition at about $60 million.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

“This acquisition provides OPKO with two late stage drug candidates, each of which holds exceptional market potential,” said Opko chairman and CEO Dr. Phillip Frost in a statement. “We believe TT401, a once-weekly dual GLP1/Glucagon agonist that recently showed success in a 420-patient phase 2 study, will complement OPKO’s existing oxyntomodulin product candidate (MOD-6031), which may provide enhanced therapeutic benefit through targeted delivery.”

Transition’s TT401 is a once- or twice-weekly oxyntomodulin to treat Type 2 diabetes and obesity. It’s the furthest along in the clinic among GLP-1/glucagon receptor dual agonists, it said.

In a Phase II study, the highest dose of TT401 peptide once weekly offered statistically significant superior weight loss versus an approved extended-release exenatide and placebo after 12 and 24 weeks of treatment.  

Opko also gains TT701, a Phase II, once-daily, oral selective androgen receptor modulator for patients with androgen deficiency.

“The selective androgen receptor modulator, TT701, could meet an important need in patients who can benefit from its anabolic effects without the risks associated with testosterone products,” Frost added. “We believe it fits well with our Claros 1 point-of-care diagnostic products under development for testosterone and PSA, which could serve as companion diagnostics.”

The deal is slated to close during the second half of this year.

- here is the release

Related Articles:
Transition Therapeutics’ woe compounded by Nasdaq delisting threat
Eli Lilly spurns a PhIII-ready diabetes drug, and Transition tanks (again)
Opko up on first FDA approval in chronic kidney disease associated indication


Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.